GMAN Newsletter – October 2015

  Vol.1 Issue¬†6 October ¬†2015   European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Empliciti (elotuzumab) On July 27th, the European Medicines Agency (EMA) validated for review the marketing authorization application for elotuzumab for the treatment of multiple myeloma for patients who have received one or more prior therapies. […]